2-(Ethoxymethyl)-4-(4-fluorophenyl)-3-[2-(2-hydroxyphenoxy)pyrimidin-4-YL]isoxazol-5(2H)-one

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-(Ethoxymethyl)-4-(4-fluorophenyl)-3-[2-(2-hydroxyphenoxy)pyrimidin-4-YL]isoxazol-5(2H)-one
• 英文别名: 2-(ethoxymethyl)-4-(4-fluorophenyl)-3-[2-(2-hydroxyphenoxy)pyrimidin-4-yl]-1,2-oxazol-5-one
• 化学式: C₂₂H₁₈FN₃O₅
• 分子量: 423.4
• InChiKey: ZSOXFJURLPCSOO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  31
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  94
• 氢给体数：
  1
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  2-甲硫基-嘧啶-4-甲醛 在 吡啶 、 chromium(VI) oxide 、 Oxone 、 羟胺 、 sodium hydride 、 三乙胺 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 为溶剂， 生成 2-(Ethoxymethyl)-4-(4-fluorophenyl)-3-[2-(2-hydroxyphenoxy)pyrimidin-4-YL]isoxazol-5(2H)-one
  参考文献：
  名称：

  The development of new isoxazolone based inhibitors of tumor necrosis factor-alpha (TNF-α) production

  摘要：

  4-Aryl-3-pyridyl and 4-aryl-3-pyrimidinyl based tumor necrosis factor-alpha (TNF-alpha) inhibitors, which contain a novel isoxazolone five-membered heterocyclic core are described. Many showed sub-micromolar activity against lipopolysaccharide-induced TNF-alpha production.

  DOI：

  10.1016/j.bmcl.2005.02.066

文献信息

• [EN] ISOXAZOLONE COMPOUNDS USEFUL IN TREATING DISEASES ASSOCIATED WITH UNWANTED CYTOKINE ACTIVITY<br/>[FR] COMPOSES D'ISOXAZOLONE UTILES POUR TRAITER DES MALADIES ASSOCIEES A UN ACTIVITE NON DESIREE DES CYTOKINES
  申请人：PROCTER & GAMBLE

  公开号：WO2002094266A1

  公开（公告）日：2002-11-28

  Isoxazolone compounds having the generic structure: are used to treat disease associated with unwanted cytokine activity, including rheumatoid arthritis, osteoarthritis, diabetes, HIV/AIDS, inflammatory bowel disease, Crohn's disease, ulcerative colitis, congestive heart, hypertension, chronic obstructive pulmonary disease, septic shock syndrome, tuberculosis, adult respiratory distress, asthma, atherosclerosis, muscle degeneration, periodontal disease, cachexia, Reiter's syndrome, gout, acute synovitis, anorexia and bulimia nervosa fever, malaise, myalgia and headaches.

  具有通用结构的异唑酮类化合物被用于治疗与不需要的细胞因子活性有关的疾病，包括风湿性关节炎、骨关节炎、糖尿病、HIV/AIDS、炎症性肠病、克罗恩病、溃疡性结肠炎、充血性心脏病、高血压、慢性阻塞性肺病、感染性休克综合征、结核、成人呼吸窘迫综合征、哮喘、动脉硬化、肌肉退化、牙周病、消瘦症、Reiter综合征、痛风、急性滑膜炎、厌食症和贪食症、发热、不适、肌痛和头痛。
• Isoxazolone compounds useful in treating diseases associated with unwanted cytokine activity
  申请人：The Procter & Gamble Company

  公开号：US20040122025A1

  公开（公告）日：2004-06-24

  Isoxazolone compounds having the generic structure: 1 are used to treat disease associated with unwanted cytokine activity, including rheumatoid arthritis, osteoarthritis, diabetes, HIV/AIDS, inflammatory bowel disease, Crohn's disease, ulcerative colitis, congestive heart, hypertension, chronic obstructive pulmonary disease, septic shock syndrome, tuberculosis, adult respiratory distress, asthma, atherosclerosis, muscle degeneration, periodontal disease, cachexia, Reiter's syndrome, gout, acute synovitis, anorexia and bulimia nervosa fever, malaise, myalgia and headaches.

  具有通用结构的异唑酮化合物1被用于治疗与不良细胞因子活性相关的疾病，包括类风湿性关节炎、骨关节炎、糖尿病、HIV/AIDS、炎症性肠病、克罗恩病、溃疡性结肠炎、充血性心脏病、高血压、慢性阻塞性肺疾病、脓毒性休克综合征、结核病、成人呼吸窘迫综合征、哮喘、动脉粥样硬化、肌肉退化、牙周病、消瘦症、Reiter综合征、痛风、急性滑膜炎、厌食症和贪食症、发热、不适、肌肉痛和头痛。
• ISOXAZOLONE COMPOUNDS USEFUL IN TREATING DISEASES ASSOCIATED WITH UNWANTED CYTOKINE ACTIVITY
  申请人：THE PROCTER & GAMBLE COMPANY

  公开号：EP1392299A1

  公开（公告）日：2004-03-03
• CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODE-GENERATIVE DISEASES SUCH AS TAUOPATHIES
  申请人：Sheridan Joseph M.

  公开号：US20140031547A1

  公开（公告）日：2014-01-30

  The invention relates to pharmaceutical compositions comprising casein kinase 1 delta (CK1δ) and to the use of said inhibitors in the treatment of neurodegenerative disorders such as Alzheimer's disease.
• CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES SUCH AS TAUOPATHIES
  申请人：Electrophoretics Limited

  公开号：US20160354375A1

  公开（公告）日：2016-12-08

  The invention relates to pharmaceutical compositions comprising casein kinase 1 delta (CK1δ) and to the use of said inhibitors in the treatment of neurodegenerative disorders such as Alzheimer's disease.